Volume 8, Issue 1, February 2019, Page: 32-35
Effect of Comprehensive Nursing Intervention on Thyroid Stimulating Hormone Suppression for Patients with Differentiated Thyroid Cancer
Zhou Miaoli, Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China
Lin Qingran, Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China
Shang Jingjie, Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China
Gong Jian, Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China
Xu Hao, Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China
Received: Dec. 2, 2018;       Accepted: Jan. 31, 2019;       Published: Feb. 27, 2019
DOI: 10.11648/j.ajns.20190801.15      View  26      Downloads  14
Abstract
Objective to investigate the effect of comprehensive nursing intervention on thyroid stimulating hormone (TSH) suppression for patients with differentiated thyroid cancer (DTC) in the Department of Nuclear Medicine. Methods From January 2016 to December 2016, a total of 90 patients with DTC, receiving 131I treatment in the Department of Nuclear Medicine of the First Affiliated Hospital of Jinan University are enrolled in this study. All patients have received TSH suppression treatment for at least 3 months prior to admission, and are given individual-based comprehensive nursing intervention on TSH suppression after admission. Through questionnaire and telephone follow-up, patients’ awareness of TSH suppression and their medication compliance before and after nursing intervention are analyzed and compared. Results The awareness of the knowledge of TSH suppression and medication compliance are significantly improved in 90 patients after comprehensive nursing intervention (P<0.05). Conclusions Individual-based comprehensive nursing intervention can effectively improve awareness of the knowledge of TSH suppression, medication compliance and confidence in cure in patients with DTC, which helps promote the harmonious relationship between nurses and patients and improve the prognosis of patients. The comprehensive nursing intervention is worthy of clinical application.
Keywords
Differentiated Thyroid Cancer, TSH Suppression, Nursing Intervention
To cite this article
Zhou Miaoli, Lin Qingran, Shang Jingjie, Gong Jian, Xu Hao, Effect of Comprehensive Nursing Intervention on Thyroid Stimulating Hormone Suppression for Patients with Differentiated Thyroid Cancer, American Journal of Nursing Science. Vol. 8, No. 1, 2019, pp. 32-35. doi: 10.11648/j.ajns.20190801.15
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Marcelino, Lopes, Madureira, Ferreira, & Limbert. (2015). Ability of the rhtsh stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up. Oncology Letters, 9 (3), 1281-1286.
[2]
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., & Dosiou, C., et al. (2017). 2017 guidelines of the american thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid, 27 (3), 315-389.
[3]
Mcleod, D. S. A., Cooper, D. S., Ladenson, P. W., Ain, K. B., Brierley, J. D., & Fein, H. G., et al. (2014). Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid Official Journal of the American Thyroid Association, 24 (1), 35-42.
[4]
Guan, H., Shan, Z., Teng, X., Li, Y., Teng, D., & Jin, Y., et al. (2010). Influence of iodine on the reference interval of tsh and the optimal interval of tsh: results of a follow-up study in areas with different iodine intakes. Clinical Endocrinology, 69 (1), 136-141.
[5]
Ovadia, Y. S., Gefel, D., Turkot, S., Aharoni, D., Fytlovich, S., & Troen, A. M. (2014). Elevated serum thyroglobulin and low iodine intake are associated with nontoxic nodular goiter among adults living near the eastern mediterranean coast. J Thyroid Res, 2014, 913672.
[6]
Moon, J. H., Kim, K. M., Oh, T. J., Choi, S. H., Lim, S., & Park, Y. J., et al. (2017). The effect of tsh-suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism, 102 (1), jc.2016-2740.
[7]
Bilezikian, J. P., Brandi, M. L., Cusano, N. E., Mannstadt, M., Rejnmark, L., & Rizzoli, R., et al. (2016). Management of hypoparathyroidism: present and future. Journal of Clinical Endocrinology & Metabolism, 101 (6), jc20153910.
[8]
Juweid, M. E., Hajjar, G., Swayne, L. C., Sharkey, R. M., Suleiman, S., & Herskovic, T., et al. (2015). Phase i/ii trial of131i-mn-14 f (ab) 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer, 85 (8), 1828-1842.
[9]
Giacobbe, A. M., Grasso, R., Triolo, O., Tonni, G., & Granese, R. (2015). Thyroid diseases in pregnancy: a current and controversial topic on diagnosis and treatment over the past 20 years. Archives of Gynecology & Obstetrics, 292 (5), 995-1002.
[10]
Dosiou, C., Barnes, J., Schwartz, A., Negro, R., Crapo, L., & Stagnarogreen, A. (2012). Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. J Clin Endocrinol Metab, 97 (97), 1536-1546.
[11]
Mannisto T, Vanmma ki M, Pouta A, et al. Thyrdd dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complication and maternal morbilith in later life. J Clin Endocfinol Metab, 2010, 95 (3): 1084-1094.
[12]
Hoftijzer, H. C., Heemstra, K. A., Corssmit, E. P., Aa, V. D. K., Romijn, J. A., & Smit, J. W. (2008). Quality of life in cured patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism, 93 (1), 200-3.
[13]
Juweid, M. E., Hajjar, G., Swayne, L. C., Sharkey, R. M., Suleiman, S., & Herskovic, T., et al. (2015). Phase i/ii trial of131i-mn-14 f (ab) 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer, 85 (8), 1828-1842.
Browse journals by subject